Bristol-Myers Squibb Profit Margin

The latest profit margin for BMY is 18.87% as of June 2026. That compares with 10.58% in the prior-year period — up 78.3% year over year. That is above the Healthcare sector average of 15.29%. Investors often review this figure alongside Bristol-Myers Squibb's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMY's profit margin moved from 10.58% to 18.87% — a 78.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb's valuation or profitability profile.

Against Healthcare companies, BMY currently prints 18.87% for profit margin, while the sector average sits near 15.29%. That is roughly 23.4% above the sector mean. Large gaps often invite a closer look at Bristol-Myers Squibb's growth, margins, and balance sheet.

Profit Margin shows how effectively Bristol-Myers Squibb converts resources into returns. At 18.87%, BMY may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 10.58% in the prior-year period — up 78.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BMY's profit margin (18.87%), review year-over-year change from 10.58%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.